Djabo Eric Adrien Tangmi, Mubarak Jolayemi Mustapha, Voufo Jolyvette Mbougo, Mubanga Ndashi Chitalu, Jonas Lotanna Ibekwe, Yee Siew Lim, Joyce Gasper Kweka, Temitayo Ayantayo, Mazin M Eltingary, Olobatoke Tunde, Marwa SaedAli Emhemed, Nicaise Kpègnon Agada, Nourou Dine Adeniran Bankole, Victor Meza Kyaruzi
{"title":"富血小板血浆治疗外伤性脑损伤疗效的系统综述","authors":"Djabo Eric Adrien Tangmi, Mubarak Jolayemi Mustapha, Voufo Jolyvette Mbougo, Mubanga Ndashi Chitalu, Jonas Lotanna Ibekwe, Yee Siew Lim, Joyce Gasper Kweka, Temitayo Ayantayo, Mazin M Eltingary, Olobatoke Tunde, Marwa SaedAli Emhemed, Nicaise Kpègnon Agada, Nourou Dine Adeniran Bankole, Victor Meza Kyaruzi","doi":"10.1093/jsprm/snad010","DOIUrl":null,"url":null,"abstract":"Abstract Traumatic brain injury (TBI) is the leading cause of death and disability worldwide and thus a significant public health concern. It can result in a range of physical, cognitive, and emotional impairments, which can significantly impact the quality of life of affected individuals and their families. Despite advances in the management of TBI, no effective treatment fully restores neurological function. Platelet-rich plasma (PRP) is a promising therapeutic approach for the treatment of TBI that has gained increasing attention in recent years. PRP is a blood product containing high concentration of platelets rich in growth factors and other bioactive molecules that can promote tissue repair and regeneration. PRP has been used in various clinical settings to accelerate healing and reduce inflammation, and there is growing evidence that it may have therapeutic benefits for TBI. This study seeks to gather evidence-based information on the therapeutic effect of PRP in the treatment of TBI. This protocol will follow the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis [PRISMA] guideline 2020. In this review, we determined four primary central databases as sources of information: PubMed, EMBASE, SCOPUS, and Cochrane Central Register of Controlled Trails. This Project was registered on the International Prospective Register of Systematic Reviews [PROSPERO]. Ethics and dissemination: Ethical approval for this study was not needed as we used alread y published studies to run this current study. Study findings will be published in journals and presented at conferences for broader dissemination. PROSPERO Registration N°: CRD42023426358.","PeriodicalId":93590,"journal":{"name":"Journal of surgical protocols and research methodologies","volume":"42 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A systematic review of the therapeutic effect of platelet-rich plasma for treating traumatic brain injury\",\"authors\":\"Djabo Eric Adrien Tangmi, Mubarak Jolayemi Mustapha, Voufo Jolyvette Mbougo, Mubanga Ndashi Chitalu, Jonas Lotanna Ibekwe, Yee Siew Lim, Joyce Gasper Kweka, Temitayo Ayantayo, Mazin M Eltingary, Olobatoke Tunde, Marwa SaedAli Emhemed, Nicaise Kpègnon Agada, Nourou Dine Adeniran Bankole, Victor Meza Kyaruzi\",\"doi\":\"10.1093/jsprm/snad010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Traumatic brain injury (TBI) is the leading cause of death and disability worldwide and thus a significant public health concern. It can result in a range of physical, cognitive, and emotional impairments, which can significantly impact the quality of life of affected individuals and their families. Despite advances in the management of TBI, no effective treatment fully restores neurological function. Platelet-rich plasma (PRP) is a promising therapeutic approach for the treatment of TBI that has gained increasing attention in recent years. PRP is a blood product containing high concentration of platelets rich in growth factors and other bioactive molecules that can promote tissue repair and regeneration. PRP has been used in various clinical settings to accelerate healing and reduce inflammation, and there is growing evidence that it may have therapeutic benefits for TBI. This study seeks to gather evidence-based information on the therapeutic effect of PRP in the treatment of TBI. This protocol will follow the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis [PRISMA] guideline 2020. In this review, we determined four primary central databases as sources of information: PubMed, EMBASE, SCOPUS, and Cochrane Central Register of Controlled Trails. This Project was registered on the International Prospective Register of Systematic Reviews [PROSPERO]. Ethics and dissemination: Ethical approval for this study was not needed as we used alread y published studies to run this current study. Study findings will be published in journals and presented at conferences for broader dissemination. PROSPERO Registration N°: CRD42023426358.\",\"PeriodicalId\":93590,\"journal\":{\"name\":\"Journal of surgical protocols and research methodologies\",\"volume\":\"42 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of surgical protocols and research methodologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jsprm/snad010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of surgical protocols and research methodologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jsprm/snad010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
外伤性脑损伤(TBI)是世界范围内导致死亡和残疾的主要原因,因此是一个重要的公共卫生问题。它会导致一系列的身体、认知和情感障碍,这可能会严重影响受影响个人及其家庭的生活质量。尽管在TBI的治疗方面取得了进展,但没有有效的治疗方法可以完全恢复神经功能。富血小板血浆(PRP)是一种很有前途的治疗方法,近年来受到越来越多的关注。PRP是一种血液制品,含有高浓度的血小板,富含生长因子和其他生物活性分子,可以促进组织修复和再生。PRP已在各种临床环境中用于加速愈合和减少炎症,并且越来越多的证据表明它可能对TBI有治疗益处。本研究旨在收集关于PRP治疗创伤性脑损伤疗效的循证信息。本方案将遵循2020年系统评价和荟萃分析(PRISMA)指南首选报告项目的标准。在这篇综述中,我们确定了四个主要的中央数据库作为信息来源:PubMed、EMBASE、SCOPUS和Cochrane central Register of Controlled Trails。该项目已在国际前瞻性系统评论登记册(PROSPERO)上注册。伦理和传播:本研究不需要伦理批准,因为我们使用了已经发表的研究来进行本研究。研究结果将在期刊上发表,并在会议上提出,以便更广泛地传播。普洛斯佩罗注册号:CRD42023426358。
A systematic review of the therapeutic effect of platelet-rich plasma for treating traumatic brain injury
Abstract Traumatic brain injury (TBI) is the leading cause of death and disability worldwide and thus a significant public health concern. It can result in a range of physical, cognitive, and emotional impairments, which can significantly impact the quality of life of affected individuals and their families. Despite advances in the management of TBI, no effective treatment fully restores neurological function. Platelet-rich plasma (PRP) is a promising therapeutic approach for the treatment of TBI that has gained increasing attention in recent years. PRP is a blood product containing high concentration of platelets rich in growth factors and other bioactive molecules that can promote tissue repair and regeneration. PRP has been used in various clinical settings to accelerate healing and reduce inflammation, and there is growing evidence that it may have therapeutic benefits for TBI. This study seeks to gather evidence-based information on the therapeutic effect of PRP in the treatment of TBI. This protocol will follow the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis [PRISMA] guideline 2020. In this review, we determined four primary central databases as sources of information: PubMed, EMBASE, SCOPUS, and Cochrane Central Register of Controlled Trails. This Project was registered on the International Prospective Register of Systematic Reviews [PROSPERO]. Ethics and dissemination: Ethical approval for this study was not needed as we used alread y published studies to run this current study. Study findings will be published in journals and presented at conferences for broader dissemination. PROSPERO Registration N°: CRD42023426358.